PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, today announced that it has recently entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy for the use of Bioject’s needle-free technology for a malaria vaccine the Navy is developing. The CRADA, titled, Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Malaria-Naïve Adults in the United States, is a two-year study that will utilize the Biojector® 2000 in human subjects.
